Shares of Eli Lilly and Company (LLY) have staged a strong comeback after dipping into the unfavored zone of the SIA S&P 100 Index Report last year, recently breaking out past $967.61 with notable technical momentum. The rally is supported by broad strength in the Drug sector and a perfect SMAX score of 10, signaling exceptional relative performance across multiple asset classes. Combined with favorable news on GLP‑1 weight-loss drug accessibility, LLY is drawing renewed attention as a leading stock in the health care sector.